The impact of baseline serum alkaline phosphatase level on the prognosis of metastatic castration-resistant prostate cancer patients treated with abiraterone

Objective To investigate the association between baseline serum alkaline phosphatase (ALP) levels and prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone. Methods The cli-nicopathologic data of 55 patients with mCRPC who received abiraterone therapy were retrospectively analyzed. Baseline serum ALP levels were measured before treatment and categorized into a high-ALP group and a normal-ALP group according to the normal cutoff (125 U/L). Differences in clinicopathological characteristics between the two groups were assessed by the log-rank test, and Kaplan-Meier survival curves were generated. A Cox regression analysis was performed to evaluate the association of baseline serum ALP level with overall survival (OS) and prostate-specific antigen progression-free survival (PSA-PFS). Results There were no significant differences in baseline characteristics between the two group, including age, number of patients with prior chemotherapy, Eastern Cooperative Oncolgy Group (ECOG) score, type of androgen deprivation therapy (ADT), Gleason score, initial se-rum PSA level, metastatic sites, neutrophil count, serum albumin level, and lactate dehydrogenase level (P>0.05). The Kaplan-Meier survival analysis results showed that both OS and PSA-PFS were shorter in the high-ALP group than in the normal-ALP group (χ2=8.91,7.44,P